VERDESO® (desonide) Foam, 0.05% is for the treatment of mild to moderate atopic dermatitis in patients 3 months of age and older. Treatment should not exceed 4 consecutive weeks.

IMPORTANT SAFETY INFORMATION for Prescription VERDESO® Foam
Systemic absorption of topical corticosteroids, including VERDESO® Foam, has produced reversible PA-axis suppression. Pediatric patients are at greater risk for HPA-axis suppression and Cushing syndrome when treated with topical steroids.

In clinical trials common adverse events were upper respiratory tract infection, cough, and application site burning.

Do not dispense directly on the face. Avoid contact with the eyes or other mucous membranes.

WARNING: Flammable. Avoid fire, flame or smoking during and immediately following application.



Prescribing Information

Prescribing Information

Download the full Prescribing Information for VERDESO® Foam.

Download



VERDESO is a registered trademark of Stiefel Laboratories, Inc.


You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.